Skip directly to search Skip directly to A to Z list Skip directly to site content
CDC Home

Volume 11, Number 8—August 2005

Research

Pseudomonas aeruginosa, Staphylococcus aureus, and Fluoroquinolone Use

Conan MacDougall*, Spencer E. Harpe*, J. Patrick Powell*, Christopher K. Johnson†, Michael B. Edmond*, and Ron E. Polk*Comments to Author 
Author affiliations: *Virginia Commonwealth University, Richmond, Virginia, USA; †Idaho State University, Boise, Idaho, USA

Main Article

Table 3

Longitudinal GEE models*

Drug FQ-R P. aeruginosa
MRSA
Coefficient p value Coefficient p value
Total FQ
Previous year's resistance 0.875 <0.001 0.804 <0.001
Total FQ use 0.002 0.883 0.025 0.155
Time -0.312 0.554 1.04 0.040
Constant 6.75 0.001 4.61 0.058
Levofloxacin
Previous year's resistance 0.868 <0.001 0.818 <0.001
Levofloxacin use 0.005 0.548 0.012 0.033
Time -0.317 0.579 1.04 0.041
Constant 6.78 0.001 6.38 0.001
Ciprofloxacin
Previous year's resistance 0.866 <0.001 0.845 <0.001
Ciprofloxacin use -0.018 0.226 -0.004 0.848
Time -0.393 0.475 0.991 0.079
Constant 8.185 <0.001 6.55 0.033

*Association of fluoroquinolone and pathogen resistance over time controlling for prior year resistance. GEE, generalized estimating equations; FQ-R P. aeruginosa, fluoroquinolone-resistant Pseudomonas aeruginosa; MRSA, methicillin-resistant Staphylococcus aureus.

Main Article

Top of Page

USA.gov: The U.S. Government's Official Web PortalDepartment of Health and Human Services
Centers for Disease Control and Prevention   1600 Clifton Rd. Atlanta, GA 30333, USA
800-CDC-INFO (800-232-4636) TTY: (888) 232-6348 - Contact CDC–INFO